All News CureVac N.V.

Equities

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.51 ^USD	-2.71%		-2.33%	-40.38%

Apr. 24	CureVac Begins Early Stage Portion of Investigational Vaccine Trial	MT
Apr. 24	CureVac Hires New Chief Business Officer	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24	MT
CureVac Hires New Chief Business Officer	Apr. 24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	Apr. 24	MT
Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024	Apr. 24
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M	Apr. 24	MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	Apr. 24	CI
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	Apr. 24	CI
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update	Apr. 24	EQ
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK	Apr. 24	EQ
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer	Apr. 24	EQ
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024	Apr. 18	EQ
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 17	AQ
CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 16	CI
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 16	EQ
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK	Apr. 04	CI
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK	Apr. 04	EQ
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK	Jan. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : An untrimmed pipeline becomes costly

November 29, 2023 at 02:56 am EST